FDA Calls Novartis' Melanoma Combo Drug a Breakthrough Post author:Sam Post published:October 22, 2017 Post category:BioPharma The FDA based its decision on data from the COMBI-AD Phase III trial. Source: BioSpace You Might Also Like FDA Slaps Clinical Hold on Concert Pharma's Hair Loss Drug May 16, 2017 Investors Sigh With Relief as bluebird bio, Celgene's CAR-T Candidate Keeps Multiple Myeloma Patients Relapse Free June 4, 2017 Exactech Expands Presence In Japan With Newly Approved Shoulder, Knee And Hip Replacement Systems June 21, 2017
Investors Sigh With Relief as bluebird bio, Celgene's CAR-T Candidate Keeps Multiple Myeloma Patients Relapse Free June 4, 2017
Exactech Expands Presence In Japan With Newly Approved Shoulder, Knee And Hip Replacement Systems June 21, 2017
